Alpha-fetoprotein-derived peptide epitope

Alpha-fetoprotein-derived peptide epitopes are specific short peptide fragments (typically 9–10 amino acids) derived from the sequence of alpha-fetoprotein, an oncofetal glycoprotein highly expressed during embryonic development and upregulated in some cancers, particularly hepatocellular carcinoma[3][6]. These peptides are presented on the surface of tumor cells by MHC class I or II molecules, where they can be recognized by cytotoxic T lymphocytes and other immune cells, making them targets for cancer immunotherapy[2][3]. Epitope-optimized AFP peptides have been developed to overcome immune tolerance and elicit stronger immune responses for therapeutic vaccination strategies[2][3]. Commonly investigated epitopes include the HLA-A*0201 restricted sites, among others, and these have been shown to be immunodominant and capable of inducing specific T cell responses in preclinical and early clinical studies[3][2][4]. The therapeutic strategy centers on activating the patient’s immune system to recognize and destroy AFP-expressing tumor cells. Note: Alpha-fetoprotein-derived peptide epitope is not itself a protein, receptor, enzyme, or classical cell-surface "therapeutic target," but rather an antigenic peptide used as a vaccine target or immune monitoring tool[2][3]. While not a receptor or enzyme, it is valid and well-recognized as a specialized molecular target in immuno-oncology.

Other names

AFP-derived peptideAFP epitopealpha-fetoprotein epitopeAFP peptide

Induction of cytotoxic T lymphocyte response through MHC class I/II restricted presentation of AFP peptides leading to tumor-specific immune attack[3][2] Immune tolerance breaking and immune system priming against tumors expressing AFP[2][3]